89bio, Inc. announced positive topline results from an open-label expansion cohort of 20 patients in the Phase Ib/IIa proof-of-concept study evaluating pegozafermin for the treatment of non-alcoholic steatohepatitis (NASH).
[89bio, Inc.]
7992332
{7992332:BBBBBBBB}
apa
50
1
171115
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
